Two years later, results from the KEYNOTE-189 and KEYNOTE-407 trials found that pembrolizumab in combination with chemotherapy resulted in the higher response rate and longer survival than platinum-based chemotherapy among metastatic non-squamous NSCLC patients as well as squamous NSCLC patients, regardless of the level of PD-L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.